苦参素注射液治疗慢性乙型肝炎临床研究

Clinical Study on Kurarinone Injection in Treating Chronic Hepatitis B

目的 :观察苦参素注射液治疗慢性乙型肝炎 (CHB)的临床疗效。方法 :治疗组 4 8例 ,对照组 5 2例 ,治疗组应用苦参素葡萄糖注射液 (天晴复欣 )及一般护肝药治疗 ,对照组只用一般护肝药治疗 ,疗程均为 3月 ,观察两组患者治疗前、治疗 1月、3月及停药 3月肝功能、肝纤维化指标、乙肝病毒标志物的变化情况。结果 :在肝功能复常方面 ,治疗 1月 ,治疗组优于对照组 ,P<0 .0 5 ,统计学处理差异有显著性意义 ;至疗程结束时两组间肝功能复常率无显著性差异 ,P >0 .0 5 ;在肝纤维化指标方面 ,治疗组肝纤维化指标较治疗前显著下降 ,P <0 .0 5 ,统计学处理差异有显著性意义 ;在HBeAg和HBVDNA阴转方面 ,治疗组明显优于对照组 ,统计学处理差异有显著性意义 ,P <0 .0 1。结论 :苦参素注射液治疗CHB具有良好疗效 ,有抗病毒、保护肝细胞。

Purpose: To observe the clinical effects of Kurarinone Injection in treating chronic hepatitis B. Method: 48 cases of the treated group were treated by Kurarinone glucose injection and common hepatinia, while 52 cases of the controlled group only by hepatinia. Both groups had three-month's treatment course. Liver function, fibrosis index of liver, change of germ marker of hepatitis B for the two groups were observed respectively before the treatment, one month and three months later in the treatment, and three months after the treatment. Results: One month later in the treatment, the treated group was superior to the controlled group in the recovery of liver function, with great significance in the statistical difference ( P <0.05). After the course of treatment, there were no remarkable difference between two groups in the recovery rate of liver function ( P >0.05); the liver fibrosis index of the treated group descended more obviously after the treatment with great significance in the statistical difference ( P <0.05). The treated group was superior to the controlled group in the transformation of HBs Ag and HBV DNA with great significance in the statistical difference ( P <0.01). Conclusion: Kurarinone injection has excellent therapeutic effect in treating chronic Hepatitis B, with the function of anti-germ, protecting liver cell and preventing liver fibrosis.